Four Knobs, and None of Them Is Glucagon

Sources

1. 011321-OR (2026) — PTT-A vs tirzepatide and CagriSema in DIO rats — Ghosh et al. (2026). Diabetes 2026;75(Supplement 1):1321-OR.

   Company abstract, ADA Scientific Sessions. Quote: “PTT-A produced dose-dependent reductions in cumulative food intake and body weight (−12% and −19% vs vehicle at 10 and 30 nmol/kg, respectively), driven by marked fat mass loss with preservation of lean mass. Tirzepatide and CagriSema each reduced body weight by approximately 12% versus vehicle.” Also: inguinal and epididymal fat reduced 36% and 50% vs 25% with tirzepatide or CagriSema; DEXA total fat-mass reduction 84 g (high-dose PTT-A) vs 60 g (either comparator); carcass analysis and MRI showed significant skeletal muscle loss with the comparators and preserved muscle with PTT-A; glucose, insulin, and triglycerides reduced. Doses: PTT-A 10 or 30 nmol/kg; tirzepatide 30 nmol/kg; CagriSema 2 nmol/kg cagrilintide plus 2 nmol/kg semaglutide; 21 days. The two-drug mix is not the same molar dose as the single peptides. Disclosures include S.S. Ghosh (consultant and shareholder, Pep2Tango) and C. Rondinone (employee and shareholder). No PMID (meeting abstract). Rat data, not a human result.

2. 0285-OR (2025) — PTT-A vs tirzepatide only; this is where 14.3 / 19.2 / 12.1 and ~26% live — Ghosh et al. (2025). Diabetes 2025;74(Supplement 1):85-OR.

   Quote: “Treatment with PTT-A at 10 and 30 nmol/kg over 21 days resulted in significant reductions in cumulative FI and BW (14.3±1.52% and 19.2±0.89% vs vehicle, respectively) driven by reductions in fat mass with no loss of muscle mass. Tirzepatide at 30 nmol/kg reduced BW only by 12.1±0.81% vs vehicle with a decrease in both fat and muscle mass. Gastrocnemius and soleus muscle weights were reduced by approximately 26% with Tirzepatide, with no reduction in muscle weight with PTT-A at same dose.” Also describes triglycerides, insulin sensitization, plasma aminotransferase, plasma lipids, hepatic triglycerides, and liver histology vs tirzepatide at equivalent doses. No CagriSema arm. These decimals are not the brackets on the ©2026 TikTok chart. No PMID. Rat data, not a human result.

3. 03299-OR (2024) — discovery abstract, including acute calcium — Ghosh et al. (2024). Diabetes 2024;73(Supplement 1):299-OR.

   Objective names a long-acting agonist for GLP-1, GIP, amylin, and calcitonin receptors. Results: acute studies in lean rodents decreased blood glucose and calcium; lean rats ate less; chronic DIO rats lost fat mass without loss of muscle mass, unlike tirzepatide in that write-up; lowered plasma insulin, alanine aminotransferase, and liver triglycerides. The published results sentence says “potent GIP, GIP, Amylin, and Calcitonin” — GLP-1 is in the title and objective, then missing in that sentence. Treated as a slip. No human bone or calcium safety package. No PMID. Rat and lean-rodent data, not a human result.

4. 04Moving Beyond GLP-1s: Preclinical Acceleration, Innovation — Marilynn Larkin (2026). Medscape.

   June 8, 2026. News report from ADA 2026. Files PTT-A with strategies “now in preclinical trials.” Repeats the 2026 abstract’s about 19% vs about 12%, fat-pad 36% and 50% vs 25%, and 84 g vs 60 g. Medscape calls tirzepatide and CagriSema “dual and triple agonists.” The abstract does not. That phrase was not used here. All co-authors reported fees from Pep2Tango, per Medscape. Preclinical meeting coverage, not a human result.

5. 05Versant Ventures Unveils Pep2Tango Therapeutics, Inc. (2024). Business Wire.

   Nov 21, 2024. Company description: unimolecular peptides targeting GLP-1, GIP, amylin, and calcitonin receptors; IND-enabling work; “An IND submission is expected in 2025.” A press-release expectation is not a trial registry and not proof a human study started.

6. 06ClinicalTrials.gov search for Pep2Tango, Oct 3, 2026 (2026). ClinicalTrials.gov.

   Query Pep2Tango via the public studies API returned no studies on Oct 3, 2026. Absence from this registry is not a complete worldwide scan. It is enough to say there is no public U.S. trial listing under that sponsor name on that date.

7. 07TikTok screen photos — New York Endocrinology (2026). Screen photos of Pep2Tango slides.

   Caption on the frames: “PTT-A is a novel, investigational unimolecular peptide tetra-agonist being developed by Pep2Tango Therapeutics.” Slides photographed off a screen: “Targeting Multiple Pharmacologies”; organ cartoon including “Preservation of muscle mass”; “PTT-A Reduces Body Weight After Chronic Treatment” (©2026 Pep2Tango Therapeutics on the chart); “PTT-A Does Not Reduce Muscle After Chronic Treatment (Carcass Analysis)”; one-chain identity graphic labeled GLP-1, GIP, amylin, calcitonin. The chain diagram is the cover of this brief. Local copies only, not a journal figure. The weight-chart’s deepest bracket reads about 19%. The other brackets are not transcribed as results. Arrows are a mechanism cartoon, not measured human outcomes. The 26% muscle line is the 2025 abstract, not a label on these photos. Preclinical company slides, not human results.

8. 08How this journal grades evidence (2026). Inspired Labs Journal.

   Live Journal brief. Grading context, not a PTT-A dataset.

9. 09What Research Use Only means (2026). Inspired Labs Journal.

   Live Journal brief. Grading context, not a PTT-A dataset. Research Use Only means laboratory research.

Educational material for laboratory research context only. Nothing here is medical advice, a protocol for human use, or a claim that Inspired Labs products diagnose, treat, cure, or prevent disease.